ADVANCED NEUROENDOCRINE CARCINOMAS UNKNOWN PRIMARY ORIGIN

Clinical trials for ADVANCED NEUROENDOCRINE CARCINOMAS UNKNOWN PRIMARY ORIGIN explained in plain language.

Never miss a new study

Get alerted when new ADVANCED NEUROENDOCRINE CARCINOMAS UNKNOWN PRIMARY ORIGIN trials appear

Sign up with your email to follow new studies for ADVANCED NEUROENDOCRINE CARCINOMAS UNKNOWN PRIMARY ORIGIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New 'Double-Action' drug trial offers hope for Tough-to-Treat digestive cancers

Disease control Recruiting now

This study is testing a new drug called tarlatamab for people with advanced neuroendocrine cancer of the digestive system or unknown origin. The trial will see if the drug works better by itself or when combined with standard chemotherapy. It aims to help patients whose cancer ha…

Matched conditions: ADVANCED NEUROENDOCRINE CARCINOMAS UNKNOWN PRIMARY ORIGIN

Phase: PHASE2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

ADVANCED NEUROENDOCRINE CARCINOMAS UNKNOWN PRIMARY ORIGIN

Get alerted when new ADVANCED NEUROENDOCRINE CARCINOMAS UNKNOWN PRIMARY ORIGIN trials appear

New 'Double-Action' drug trial offers hope for Tough-to-Treat digestive cancers